Lexeo Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.6%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| LX2020 PKP2-ACM High-Dose 12-Month Data Update | 31 Dec 2026 |
| SUNRISE-FA 2 Topline Data Readout | 31 Dec 2027 |
| Anticipated BLA Submission for LX2006 under Accelerated Approval Pathway | 30 Jun 2028 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly227.6MTarget: Sufficient to fund operations into 2028
SUNRISE-FA 2 Pivotal Trial Enrollment QuarterlyTarget: Complete enrollment of 26 participants (13 treated, 13 untreated)
Mean Left Ventricular Mass Index (LVMI) Reduction AnnuallyTarget: Statistically significant reduction at 6 months (Phase I/II showed 18-23% mean reduction)
Watch Items
- FDA feedback on confirmatory evidence strategy for SUNRISE-FA 2Trigger: Alignment on secondary endpoints at 12 months to support full approvalAction: Update clinical development plan and regulatory timeline
- LX2020 PKP2-ACM High-Dose 12-Month Data UpdateTrigger: Data release scheduled for Q4 2026Action: Evaluate efficacy in reducing premature ventricular contractions and safety profile
- SUNRISE-FA 2 Topline Data ReadoutTrigger: Data release scheduled for H2 2027Action: Prepare Biologics License Application (BLA) submission if positive
Research as of 19 Jun 2026